DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2014/022012.6 A1 Tygesen Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2014/022012.6 A1 Tygesen Et Al US 2014022O126A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/022012.6 A1 Tygesen et al. (43) Pub. Date: Aug. 7, 2014 (54) ABUSE-DETERRENT PHARMACEUTICAL (60) Provisional application No. 61/668,741, filed on Jul. 6, COMPOSITIONS FOR CONTROLLED 2012. RELEASE (30) Foreign Application Priority Data (71) Applicant: EGALET LTD., LONDON (GB) Jul. 6, 2012 (DK) ........................... PA 2012 70405 (72) Inventors: Peter Holm Tygesen, Vaerlose (DK); Karsten Lindhardt, Haslev (DK); Publication Classification Martin Rex Olsen, Holbaek (DK); Gina Engslev Fischer, Vaerlose (DK); Jan (51) Int. Cl. Martin Overgard, Frederikssund (DK); A619/20 (2006.01) Georg Boye, Hedehusene (DK); Nikolaj A613 L/485 (2006.01) Skak, Virum (DK); Torben Elhauge, (52) U.S. Cl. Copenhagen K (DK) CPC ............. A61K9/2031 (2013.01); A61 K3I/485 (2013.01) (73) Assignee: EGALET LTD., LONDON (GB) USPC ........................................... 424/465; 514/282 (21) Appl. No.: 14/249,965 (57) ABSTRACT (22) Filed: Apr. 10, 2014 The present disclosure relates to pharmaceutical composi Related U.S. Application Data tions that are abuse resistant and may also provide controlled (63) Continuation of application No. 13/933,053, filed on release. The present disclosure also relates to the use of phar Jul. 1, 2013. maceutical compositions in the treatment of pain. Patent Application Publication Aug. 7, 2014 Sheet 1 of 20 US 2014/022O126 A1 3. f s ls- iss-se a Ry,------ ---. -&--- res ---Y --- -a- r \Y. t N ^F Fig. 1 Patent Application Publication Aug. 7, 2014 Sheet 2 of 20 US 2014/022O126 A1 Fig. 2 Patent Application Publication Aug. 7, 2014 Sheet 3 of 20 US 2014/022O126 A1 Patent Application Publication Aug. 7, 2014 Sheet 4 of 20 US 2014/022O126 A1 OO . 80 8 . i 8 40 Y --57F-51A 2 O -- 1577-051A coffee grinded 15 sec Time (min) Fig. 4 Patent Application Publication Aug. 7, 2014 Sheet 5 of 20 US 2014/022O126 A1 28: ------------------------- % 80% {u:iative % 24.5% fe.9% Size interva as Fractiles 10% fractile 25% fractile 50% fractile f5% fractile 90% fractile Fig. 5 Patent Application Publication Aug. 7, 2014 Sheet 6 of 20 US 2014/022O126 A1 s - 1577-051B Untampered Buffer pH 6.8 i 4 40% why etiao - 1577-051B ampered Buffer pH 6.8 f 40% ww ethano 2 -o-1577-051B Untampered Buffer ph 6.8 O 2 3 4 O SO SOO f 8O 900 Tine (min) Fig. 6 Patent Application Publication Aug. 7, 2014 Sheet 7 of 20 US 2014/022O126 A1 - 9% 80% 63% i:riate % 37.9% f3.3% 88% Size interfa as Fractiles 10% fractile 25% fractile 50% fractile f5% fractile 90% fractile Fig. 7 Patent Application Publication Aug. 7, 2014 Sheet 8 of 20 US 2014/022O126 A1 --581065 --581-065 Coffee grinder 5 Sec if cus O 2 3. 40 SO SO Time (min) Fig. 8 Patent Application Publication Aug. 7, 2014 Sheet 9 of 20 US 2014/022O126 A1 --- 3: 83% 6% ... A8, * N Freq:ency s:- Citatisfa ; - 285 Size interwat aris) Fractiles 10% fractile 25% fractile 50% fractile A5% fractile 90% fractile Fig. 9 Patent Application Publication Aug. 7, 2014 Sheet 10 of 20 US 2014/022O126 A1 100 90 80 70 60 50 40 30 2 -0-158.066 Untampered 1C -H1583-066 Tampered Time (min) Fig. 10 Patent Application Publication Aug. 7, 2014 Sheet 11 of 20 US 2014/022O126 A1 8% & Fiegency ::iiative 8 779 : 388 88, 8.3% Size interia as Fractiles 10% fractile 25% fractile 50% fractile 75% fractile 90% fractile Fig. 11 Patent Application Publication Aug. 7, 2014 Sheet 12 of 20 US 2014/022O126 A1 100 90 80 70 60 50 40 30 2O --OxyContin OP 40 mg. Jntampered 10 -HOxyContin OP 4.3 mg Tampered 2 sec O 2O: 4. 66 3CO OO 1200 Time (min) Fig. 12 Patent Application Publication Aug. 7, 2014 Sheet 13 of 20 US 2014/022O126 A1 & Faciency Fractiles 10% fractile 25% fractile 50% fractile f5% fractile 90% fractile Fig. 13 Patent Application Publication Aug. 7, 2014 Sheet 14 of 20 US 2014/022O126 A1 110 100 -------------------------- 90 -- 80 70 60 50 ----2-QQ60-Q67, buffer pH 6.8 40 30 - 2-0.066-067, buffer phi 6.8, 20 40%, wif wethano 10 O 2 3) & S SO SO 9 11 Time (min) Fig. 14 Patent Application Publication Aug. 7, 2014 Sheet 15 of 20 US 2014/022O126 A1 100.0 A ------------------ ----------- ?' - a 8O,O : ,' ar - & OxyContin CP 40 mg, ampered r -- St Continus 60 mg, ampered s ? f * - Morphine 230 mg, ampered 60,0 f are OxyContin OP40 mg, Jrtarr pered ,' ? --MS: Continus 60 mg, Untampered 40, -: f --Morphine 230 mg, Untampered 20, O. 10,0 200 30,0: 400 50,0 6O, O. Time (min) Fig. 15 Patent Application Publication Aug. 7, 2014 Sheet 16 of 20 US 2014/022O126 A1 100 80 d O --Opana ER 40 mg, Tampered 20 --OxyContin OP 80 mg, Tampered -e-Morphine 200 mg, Tampered -HMST continus 60 mg, Tampered O 2O 30 40 5 6. Time (min) Fig. 16 Patent Application Publication Aug. 7, 2014 Sheet 17 of 20 US 2014/022O126 A1 12-COSS-OS ŠFrixus. 8:8:umulaifi Size interslum) Fractiles 10% fractile 25% fractile 50% fractile A5% fractile 90% fractile Fig. 17 Patent Application Publication Aug. 7, 2014 Sheet 18 of 20 US 2014/022O126 A1 MST Continus &Fury uulsati's Sirts) Fractiles 10% fractile 25% fractile 50% fractile 75% fractile 90% fractile Fig. 18 Patent Application Publication Aug. 7, 2014 Sheet 19 of 20 US 2014/022O126 A1 ŠFuse :Currhulsif's Frequency Cumulativ Naša. aiaasa Sieterial Fractiles 10% fractile 25% fractile 50% fractile A5% fractile 90% fractile Fig. 19 Patent Application Publication Aug. 7, 2014 Sheet 20 of 20 US 2014/022O126 A1 SFreunity & Cumultifs Seiteral) Fractiles 10% fractile 25% fractile 50% fractile f5% fractile 90% fractile Fig. 20 US 2014/0220 126 A1 Aug. 7, 2014 ABUSE-DETERRENT PHARMACEUTICAL 0010 FIG. 5 shows particle size reduction results of one COMPOSITIONS FOR CONTROLLED embodiment of a ground (tampered) pharmaceutical compo RELEASE sition, as disclosed herein, comprising PEO 400,000 daltons. 0011 FIG. 6 shows in vitro dissolution results of the RELATED APPLICATIONS release of oxycodone (%) versus time (minutes) in phosphate buffer solution pH 6.8 with and without 40% V/v ethanol. The 0001. This application claims the benefit of U.S. Provi release of oxycodone is shown for intact tablets (untampered) sional Application No. 61/668,741, filed on Jul. 6, 2012, the and ground tablets (tampered) of one embodiment of a phar contents of which are incorporated herein by reference. maceutical composition, as disclosed herein, comprising 0002 All patent and non-patent references cited in the PEO 600,000 daltons. application are hereby incorporated by reference in their 0012 FIG. 7 shows particle size reduction results of one entirety. embodiment of a ground (tampered) pharmaceutical compo sition as disclosed herein comprising PEO 600,000 daltons. FIELD OF INVENTION 0013 FIG. 8 shows in vitro dissolution results of the 0003. The present disclosure relates to pharmaceutical release of hydromorphone (%) versus time (minutes) in phos compositions. In certain embodiments, the pharmaceutical phate buffer solution pH 6.8. The release of hydromorphone compositions according to the present description are abuse is shown for intact tablets (untampered) and ground tablets (tampered) of one embodiment of a pharmaceutical compo deterrent and may provide controlled release. sition, as disclosed herein, comprising PEO 2,000,000 dal BACKGROUND OF INVENTION tOnS. 0014 FIG. 9 shows particle size reduction results of one 0004 Increased attention has been drawn to the abuse of embodiment of a ground (tampered) pharmaceutical compo prescription pharmaceutical compositions. The abuse, or sition, as disclosed herein, comprising PEO 2,000,000 dal non-medicinal use, of prescription pharmaceutical composi tOnS. tions has been reported to be an increasing problem. In North 0015 FIG. 10 shows in vitro dissolution results of the America, abuse of prescription pharmaceutical compositions release of oxymorphone (%) versus time (minutes) in phos has become an important issue for the U.S. Food and Drug phate buffer solution pH 6.8. The release of oxymorphone is Administration (FDA), and the pharmaceutical industry is shown for intact tablets (untampered) and ground tablets striving to develop abuse-deterrent pharmaceutical composi (tampered) of one embodiment of a pharmaceutical compo tions in order to reduce the potential for misuse of prescrip sition as disclosed herein comprising PEO 10,000,000 dal tion pharmaceutical compositions. Prescription pharmaceu tOnS. tical compositions that are typically misused fall, primarily, 0016 FIG. 11 shows particle size reduction results of one into three groups: 1) Opioids prescribed for pain; 2) Central embodiment of a ground (tampered) pharmaceutical compo Nervous System (CNS) depressants prescribed for anxiety or sition as disclosed herein comprising PEO 10,000,000 dal sleep problems; and 3) Stimulants, prescribed, for example, tOnS. for attention deficit hyperactivity, narcolepsy, or obesity. 0017 FIG. 12 shows in vitro dissolution results of the 0005 Methods for abusing prescription pharmaceutical release of oxycodone (%) versus time (minutes) in phosphate compositions are varied and can include, for example, extrac buffer solution pH 6.8. The release of oxycodone is shown for tion, melting, Volatilization, physical tampering (e.g., grind intact tablets (untampered) and ground tablets (tampered) of ing, grating, crushing, etc.), or direct administration. For pur OxycontinR OP40 mg. poses of abuse, methods of administering active drug 0018 FIG. 13 shows particle size reduction results of a Substances obtained from prescription pharmaceutical com ground OxycontinR OP40 mg tablet. positions or of the pharmaceutical compositions themselves 0019 FIG. 14 shows in vitro dissolution results of the are similarly diverse and include, for example, injection, release of morphine (%) versus time (minutes) in phosphate Smoking, Snorting, Swallowing, Sublingual or buccal admin buffer solution pH 6.8 with and without 40% V/v ethanol.
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • UNIVERSITE DE NANTES Thomas Gelineau
    UNIVERSITE DE NANTES __________ FACULTE DE MEDECINE __________ Année 2011 N° 139 THESE pour le DIPLÔME D’ÉTAT DE DOCTEUR EN MÉDECINE DES de médecine générale par Thomas Gelineau né le 29 janvier 1983 à Cholet __________ Présentée et soutenue publiquement le 06/12/2011 __________ LE RHUME DE L'ENFANT ET SON TRAITEMENT: DECISION PARTAGEE AVEC LES PARENTS D'APRES UN QUESTIONNAIRE __________ Président : Monsieur le Professeur Olivier MALARD Directeur de thèse : Madame le Professeur Jacqueline LACAILLE 1 Table des matières IIntroduction................................................................................................................ 7 IIDéfinition, état des connaissances...........................................................................8 1Le rhume.......................................................................................................................................8 APhysiopathologie............................................................................................................................. 8 aL'origine virale.................................................................................................................................... 8 bLa saisonnalité................................................................................................................................... 8 cL'âge de survenue.............................................................................................................................. 9 dLe sexe..................................................................................................................................................
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • General Pharmacology
    GENERAL PHARMACOLOGY Winners of “Nobel” prize for their contribution to pharmacology Year Name Contribution 1923 Frederick Banting Discovery of insulin John McLeod 1939 Gerhard Domagk Discovery of antibacterial effects of prontosil 1945 Sir Alexander Fleming Discovery of penicillin & its purification Ernst Boris Chain Sir Howard Walter Florey 1952 Selman Abraham Waksman Discovery of streptomycin 1982 Sir John R.Vane Discovery of prostaglandins 1999 Alfred G.Gilman Discovery of G proteins & their role in signal transduction in cells Martin Rodbell 1999 Arvid Carlson Discovery that dopamine is neurotransmitter in the brain whose depletion leads to symptoms of Parkinson’s disease Drug nomenclature: i. Chemical name ii. Non-proprietary name iii. Proprietary (Brand) name Source of drugs: Natural – plant /animal derivatives Synthetic/semisynthetic Plant Part Drug obtained Pilocarpus microphyllus Leaflets Pilocarpine Atropa belladonna Atropine Datura stramonium Physostigma venenosum dried, ripe seed Physostigmine Ephedra vulgaris Ephedrine Digitalis lanata Digoxin Strychnos toxifera Curare group of drugs Chondrodendron tomentosum Cannabis indica (Marijuana) Various parts are used ∆9Tetrahydrocannabinol (THC) Bhang - the dried leaves Ganja - the dried female inflorescence Charas- is the dried resinous extract from the flowering tops & leaves Papaver somniferum, P album Poppy seed pod/ Capsule Natural opiates such as morphine, codeine, thebaine Cinchona bark Quinine Vinca rosea periwinkle plant Vinca alkaloids Podophyllum peltatum the mayapple
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • WO 2016/154503 Al 29 September 2016 (29.09.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/154503 Al 29 September 2016 (29.09.2016) P O P C T (51) International Patent Classification: Saujanya; 33 12 Cornelia Court, Jamestown, NC 27282 A61K 9/48 (2006.01) A61K 47/12 (2006.01) (US). YANG, Chue; 302 Kensington Road, Greensboro, A61K 9/64 (2006.01) A61K 47/42 (2006.01) NC 27403 (US). VAN DUIJNHOVEN, Henricus A61K 9/66 (2006.01) Marinus, Gerardus, Maria; Loevestein 9, 5235 GC Den Bosch (NL). PIEST, Martin; Smijersstraat 66, 5012 CD (21) International Application Number: Tilburg (NL). FATMI, Aqeel, A.; 4125 Premier Drive, PCT/US20 16/024 127 High Point, NC 27265 (US). (22) International Filing Date: (74) Agent: BROWN, Bernard, A., II; Brinks Gilson & Lione, 25 March 2016 (25.03.2016) Post Office Box 110285, Research Triangle Park, NC (25) Filing Language: English 27709 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 62/138,468 26 March 2015 (26.03.2015) US BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 62/236,297 2 October 201 5 (02. 10.2015) US DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (71) Applicant: BANNER LIFE SCIENCES LLC [US/US]; HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4125 Premier Drive, High Point, NC 27265 (US).
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]